Neratinib (HKI-272) in the treatment of breast cancer

Future Oncology

Volumn 8, Issue 6, 2012, Pages 671-681

  López Tarruella, Sara ^a   Jerez, Yolanda ^a   Márquez Rodas, Iván ^a   Martín, Miguel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

breast cancer; neratinib; oral pan HER 2 kinase inhibitor

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; AFATINIB; ALVESPIMYCIN; CAPECITABINE; CARBOPLATIN; CYCLIN D1; CYCLOPHOSPHAMIDE; DALOTUZUMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FIGITUMUMAB; GANITUMAB; KETOCONAZOLE; LAPATINIB; LETROZOLE; METFORMIN; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PLACEBO; PROTEIN P27; RETASPIMYCIN; TEMSIROLIMUS; TRASTUZUMAB; TREBANANIB; VELIPARIB;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ANOREXIA; ANTIPROLIFERATIVE ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; STOMACH CANCER; VOMITING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84863676239     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.66     Document Type: Review

References (53)

1. Citri A, Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 7(7), 505-516 (2006).
2. Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: An erb B-related gene encoding a 185,000 Mr tumour antigen. Nature 312(5994), 513-516 (1984).
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER 2/neu oncogene. Science 235(4785), 177-182 (1987).
4. Slamon DJ, Dekernion JB, Verma IM, Cline MJ. Expression of cellular oncogenes in human malignancies. Science 224(4646), 256-262 (1984).
5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER 2 receptor and breast cancer: Ten years of targeted anti-HER 2 therapy and personalized medicine. Oncologist 14(4), 320-368 (2009).
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
9. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8), 809-820 (2006).
10. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273-1283 (2011).
11. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized Phase III TAnDEM study. J. Clin. Oncol. 27(33), 5529-5537 (2009).
12. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27(34), 5838-5847 (2009).
13. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res. 15(24), 7479-7491 (2009).
14. Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available. Clin. Cancer Res. 17(5), 952-958 (2011).
15. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
16. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27(33), 5538-5546 (2009).
17. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J. Clin. Oncol. 27(12), 1999-2006 (2009).
18. García-Sáenz JA, Martín M, Puente J et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin. Breast Cancer 6(4), 325-329 (2005).
19. Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
20. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28(7), 1124-1130 (2010).
21. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, Phase 3 trial. Lancet 379(9816), 633-640 (2012).
22. Gianni L, Pienkowski T, Im YH et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized Phase II study ('NeoSphere'). Cancer Res. 70(24 Suppl. 2), Abstract S3 2 (2010).
23. Schneeweiss A, Chia S, Hickish T et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: A randomized Phase II study (TRYPHAENA). Cancer Res. 71(24 Suppl. 3), Abstract S5 6 (2011).
24. Baselga J, Kim S-B, Im SA et al. A Phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA). Cancer Res. 71(Suppl. 24), Abstract S5 5 (2011).
25. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 9(1), 16-32 (2011).
26. Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer. Arch. Pharm. (Weinheim) 341(8), 465-477 (2008).
27. Bose P, Ozer H. Neratinib: An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig. Drugs 18(11), 1735-1751 (2009).
28. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10(4), 307-317 (2011).
29. Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr. Opin Chem. Biol. 14(4), 475-480 (2010).
30. Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308(5726), 1318-1321 (2005).
31. Tsou HR, Overbeek-Klumpers EG, Hallett WA et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 48(4), 1107-1131 (2005).
32. Wissner A, Overbeek E, Reich MF et al. Synthesis and structure-Activity relationships of 6,7-disubstituted 4-Anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER 2). J. Med. Chem. 46(1), 49-63 (2003).
33. Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER 2 tyrosine kinase. Cancer Res. 64(11), 3958-3965 (2004).
34. Bennett R, Gijsen M, Kong A. Overcoming trastuzumab resistance with the irreversible pan-HER inhibitor neratinib. Cancer Res. 71(8 Suppl. 1), Abstract 1737 (2011).
35. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012).
36. Seyhan AA, Varadarajan U, Choe S et al. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments. Mol. Biosyst. 7(6), 1974-1989 (2011).
37. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102(21), 7665-7670 (2005).
38. Ji H, Zhao X, Yuza Y et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl Acad. Sci. USA 103(20), 7817-7822 (2006).
39. Godin-Heymann N, Ulkus L, Brannigan BW et al. The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 7(4), 874-879 (2008).
40. Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105(6), 2070-2075 (2008).
41. Wong KK, Fracasso PM, Bukowski RM et al. A Phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res. 15(7), 2552-2558 (2009).
42. Wang J, Li-Chan XX, Atherton J et al. Characterization of HKI-272 covalent binding to human serum albumin. Drug Metab. Dispos. 38(7), 1083-1093 (2010).
43. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. Pharmacokinetics of oral neratinib during co-Administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 71(4), 522-527 (2011).
44. Ito Y, Hatake K, Takahashi S et al. Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors. J. Clin. Oncol. 27(Suppl), Abstract e14505 (2009).
45. Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A Phase I/II study. J. Clin. Oncol. 27(Suppl. 15), Abstract 1004 (2009).
46. Limentani SA, Awada A, Dirix L et al. Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors. J. Clin. Oncol. 27(Suppl), Abstract e14554 (2009).
47. Chow L, Jiang Z, Epstein R et al. Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors. J. Clin. Oncol. 27(Suppl. 15), Abstract 3557 (2009).
48. Ito Y, Hatake K, Takahashi S et al. A Phase 1 study of neratinib (HKI-272) in combination with paclitaxel in Japanese patients with solid tumors. Presented at: E UROPEAN Society for Medical Oncology (ESMO) 2010. Milan, Italy, 8-10 October 2010.
49. Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D. A single-dose, crossover, placebo-And moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. J. Clin. Oncol. 28(Suppl), Abstract e11070 (2010).
50. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28(8), 1301-1307 (2010).
51. Martin M, Bonneterre J, Geyer CE Jr et al. A Phase 2 randomized trial of neratinib monotherapy vs. lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. J. Clin. Oncol. (2012) (In Press).
52. Saura C, Martin M, Moroose R et al. Safety of neratinib (HKI-272) in combination with capecitabine in patients with solid tumors. A Phase 1/2 study. Cancer Res. 69(24 Suppl. 3), Abstract 5108 (2010).
53. Saura C, Garcia Saenz JA, Xu B et al. Safety and efficacy of neratinib in combination with capecitabine in patients with ErbB2-positive breast cancer. Lancet Oncol. (2012) (In Press).